Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease

Jiong Shi; Jacques Touchon; Lefkos T. Middleton; Mercé Boada Rovira; Robert Vassar; Bruno Vellas; Yong Shen

doi:10.1016/j.scib.2024.09.042

Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease

Jiong Shi^*, Jacques Touchon, Lefkos T. Middleton, Mercé Boada Rovira, Robert Vassar, Bruno Vellas, Yong Shen

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

After a number of failed drug studies on Alzheimer's disease (AD) over the past decade, clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use. However, controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets. The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD, i.e., amyloid-β (Aβ) and tau protein, and to explore other targets such as anti-inflammation in AD. The complex pathophysiology of AD may require combination therapies rather than monotherapy. Throughout the course of AD, multiple pathways are disrupted, presenting a multitude of possible therapeutic targets for designing prevention and intervention for AD.

Original language	English (US)
Pages (from-to)	3777-3784
Number of pages	8
Journal	Science Bulletin
Volume	69
Issue number	23
DOIs	https://doi.org/10.1016/j.scib.2024.09.042
State	Published - Dec 15 2024

Funding

This work was supported by the National Key Plan for Scientific Research and Development of China (2020YFA0509304), the Chinese Academy of Sciences (XDB39000000), the National Natural Sciences Foundation of China (82030034 and 32121002), CAMS Innovation Fund for Medical Sciences (IFMS) (2021-I2M-C&T-B-012), the Fundamental Research Funds for the Central Universities (YD9110002027 and YD9110002033), Anhui Provincial Key R&D Programs (202304295107020056) and the Guangzhou Key Research Program on Brain Science (202007030008). Jiong Shi, Yong Shen, and Bruno Vellas designed this article. Jacques Touchon, Lefkos T Middleton, Merc\u00E9 Boada Rovira and Robert Vassar participated in the discussion of the article's structure, information gathering, and revisions of the manuscript. Jiong Shi wrote the draft of the manuscript. All authors have reviewed and approved the final version of the article. This work was supported by the National Key Plan for Scientific Research and Development of China (2020YFA0509304), the Chinese Academy of Sciences (XDB39000000), the National Natural Sciences Foundation of China (82030034 and 32121002), CAMS Innovation Fund for Medical Sciences (IFMS) (2021-I2M-C&T-B-012), the Fundamental Research Funds for the Central Universities (YD9110002027 and YD9110002033), Anhui Provincial Key R&D Programs (202304295107020056) and the Guangzhou Key Research Program on Brain Science (202007030008).

Keywords

Alzheimer's disease
Amyloid
Biomarker
Dementia
Tau
Treatment

ASJC Scopus subject areas

General

Access to Document

10.1016/j.scib.2024.09.042

Cite this

@article{2a953c5ef2b64821adb24732601e8965,

title = "Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease",

abstract = "After a number of failed drug studies on Alzheimer's disease (AD) over the past decade, clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use. However, controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets. The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD, i.e., amyloid-β (Aβ) and tau protein, and to explore other targets such as anti-inflammation in AD. The complex pathophysiology of AD may require combination therapies rather than monotherapy. Throughout the course of AD, multiple pathways are disrupted, presenting a multitude of possible therapeutic targets for designing prevention and intervention for AD.",

keywords = "Alzheimer's disease, Amyloid, Biomarker, Dementia, Tau, Treatment",

author = "Jiong Shi and Jacques Touchon and Middleton, {Lefkos T.} and Rovira, {Merc{\'e} Boada} and Robert Vassar and Bruno Vellas and Yong Shen",

note = "Publisher Copyright: {\textcopyright} 2024 Science China Press",

year = "2024",

month = dec,

day = "15",

doi = "10.1016/j.scib.2024.09.042",

language = "English (US)",

volume = "69",

pages = "3777--3784",

journal = "Science Bulletin",

issn = "2095-9273",

publisher = "Elsevier B.V.",

number = "23",

}

TY - JOUR

T1 - Now and future

T2 - Strategies for diagnosis, prevention and therapies for Alzheimer's disease

AU - Shi, Jiong

AU - Touchon, Jacques

AU - Middleton, Lefkos T.

AU - Rovira, Mercé Boada

AU - Vassar, Robert

AU - Vellas, Bruno

AU - Shen, Yong

PY - 2024/12/15

Y1 - 2024/12/15

N2 - After a number of failed drug studies on Alzheimer's disease (AD) over the past decade, clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use. However, controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets. The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD, i.e., amyloid-β (Aβ) and tau protein, and to explore other targets such as anti-inflammation in AD. The complex pathophysiology of AD may require combination therapies rather than monotherapy. Throughout the course of AD, multiple pathways are disrupted, presenting a multitude of possible therapeutic targets for designing prevention and intervention for AD.

AB - After a number of failed drug studies on Alzheimer's disease (AD) over the past decade, clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use. However, controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets. The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD, i.e., amyloid-β (Aβ) and tau protein, and to explore other targets such as anti-inflammation in AD. The complex pathophysiology of AD may require combination therapies rather than monotherapy. Throughout the course of AD, multiple pathways are disrupted, presenting a multitude of possible therapeutic targets for designing prevention and intervention for AD.

KW - Alzheimer's disease

KW - Amyloid

KW - Biomarker

KW - Dementia

KW - Tau

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85207035899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85207035899&partnerID=8YFLogxK

U2 - 10.1016/j.scib.2024.09.042

DO - 10.1016/j.scib.2024.09.042

M3 - Review article

C2 - 39443183

AN - SCOPUS:85207035899

SN - 2095-9273

VL - 69

SP - 3777

EP - 3784

JO - Science Bulletin

JF - Science Bulletin

IS - 23

ER -

Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this